Long-term use of rivastigmine in patients with dementia with Lewy bodies: an open-label trial


Grace, Janet, Daniel, Sarah, Stevens, Timothy, Shankar, K. Shankar, Walker, Zuzanna, Byrne, E. Jane, Butler, Susan, Wilkinson, David, Woolford, Jan, Waite, Jonathon and McKeith, Ian G. (2001) Long-term use of rivastigmine in patients with dementia with Lewy bodies: an open-label trial. International Psychogeriatrics, 13, (2), 199-205. (doi:10.1017/S104161020100758X).

Download

Full text not available from this repository.

Description/Abstract

Patients with dementia with lewy bodies (DLB) have progressive deficits in cognition, parkinsonism, and neuropsychiatric symptoms. Cholinesterase inhibitors have been used to ameliorate cognitive decline and neuropsychiatric symptoms in short-term trials. In this study, patients with DLB were treated with rivastigmine up to 96 weeks. Improvement from baseline was seen in cognitive function as measured by the Mini-Mental State Examination (MMSE), and neuropsychiatric symptoms as measured by the Neuropsychiatric Inventory (NPI) over the first 24 weeks of treatment. By 96 weeks, neither the MMSE scores nor the NPI scores were significantly worse than at baseline.

Item Type: Article
ISSNs: 1041-6102 (print)
Related URLs:
Subjects: R Medicine > RC Internal medicine > RC0321 Neuroscience. Biological psychiatry. Neuropsychiatry
R Medicine > RM Therapeutics. Pharmacology
Divisions: University Structure - Pre August 2011 > School of Medicine > Clinical Neurosciences
ePrint ID: 27578
Date Deposited: 28 Apr 2006
Last Modified: 27 Mar 2014 18:16
URI: http://eprints.soton.ac.uk/id/eprint/27578

Actions (login required)

View Item View Item